- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03545685
Intervention of Attenuated Psychosis Syndrome With M-Health Technology
July 31, 2019 updated by: Florida A&M University
Enhancing Intervention of Attenuated Psychosis Syndrome With M-Health Technology
The investigators will develop a culturally sensitive smart phone application to enhance neurocognitive function (memory and attention in particular) of participants with attenuated psychosis syndrome (APS).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigator will conduct a pilot study of 80 APS subjects (age 18-45).
Forty subjects will be randomly put in the SMART plus routine care (RC) group and 40 to RC group only.
At baseline and 3-month follow-ups, all subjects will complete questionnaires including Mobile App Rating Scale SMART feasibility and engagement.
1:1 in-depth interviews will be conducted at the two time points to cross-validate the findings obtained from the questionnaires.
The questionnaires and in-depth interviews for APS subjects for the RC group seek to explore their preference and likelihood to use SMART given the opportunity.
Examine Cognitive Function Change.
In order to prepare for future large scale randomized clinical trials, the investigator will examine the effectiveness of SMART in improving working memory and attention of APS subjects.
At baseline and 3-month follow-ups, all subjects will complete MATRICS Consensus Cognitive Battery (MCCB) subtests measuring working memory (Spatial Span) and attention (Continuous Performance Test-Identical Pairs).
A between and within group design allows examining change of outcome variables over time and group differences.
Enhance mHealth research capacity of SMHC at individual and organization levels.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shangai, China
- Shanghai Mental Health Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 18 and 45 years old.
- Understand and sign an informed consent (or assent for minors) document.
- Must meet the substance use criteria: No DSM IV Alcohol or Drug Dependence in the past 3 months; No use on the day of assessment, clearly not high or hung-over.
Meet diagnostic criteria for a prodromal syndrome. If under the age of 19 and meets diagnostic criteria for Schizotypal Personality Disorder or meets the diagnostic criteria called the Criteria for Prodromal Syndromes (COPS) which are operationalized as follows:
- Genetic Risk and Deterioration Syndrome (GRDS): First degree relative with psychosis or subject with Schizotypal Personality Disorder and a 30% drop in GAF score compared to one year ago, sustained over the past month, or
- Attenuated Positive Symptoms Syndrome (APSS): Severity rating of moderate (rating of 3), moderately severe (4) or severe but not psychotic (5) on any one of the five SOPS positive symptoms; symptom occurs at above severity level at an average frequency of at least once per week in the past month; symptom must have begun in the past year or currently rates at least one scale point higher than rated 12 months previously, or
- Brief Intermittent Psychotic Syndrome (BIPS): Severity rating of psychotic intensity (6) on any of the 5 SOPS positive symptoms 94; symptom is present at least several minutes per day at a frequency of at least once per month; symptom(s) must have reached a psychotic intensity in the past 3 months; symptom is not seriously disorganizing or dangerous; symptom(s) do not last for more than 1 hour/day at an average frequency of 4 days/week over 1 month.
Exclusion Criteria:
- Meet criteria for current or lifetime Axis I psychotic disorder, including affective psychoses and psychosis NOS.
- Impaired intellectual functioning (i.e. IQ<70).
- Past or current history of a clinically significant central nervous system disorder that may contribute to prodromal symptoms or confound their assessment.
- Traumatic Brain Injury that is rated as 7 or above on the Traumatic Brain Injury screening instrument (signifying a significant brain injury with persistent sequelae).
- The diagnostic prodromal symptoms are clearly caused by an Axis 1 disorder, including substance use disorders, in the judgment of the evaluating clinician. Other non-psychotic disorders will not be exclusionary (e.g. substance abuse disorder, major depression, anxiety disorders, Axis II Disorders), as long as the disorder does not account for the diagnosis of prodromal symptoms.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SMART
The subjects in SMART training group will receive add-on SMART intervention for 3 months.
Subjects will play cognitive games for 1 hour per day, five days per week.
SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities.
Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time.
Top 5 APS subjects who play the game for the most time in a week will be rewarded
|
The investigator will conduct a pilot study of 80 APS subjects (age 18-45).
The investigator will examine SMART feasibility and user engagement using a randomized control trial research design.
Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention.
At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement.
In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
|
Other: Control group
Participants in this group will serve as control group
|
The investigator will conduct a pilot study of 80 APS subjects (age 18-45).
The investigator will examine SMART feasibility and user engagement using a randomized control trial research design.
Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention.
At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement.
In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Memory and attention scores
Time Frame: 3rd month
|
Memory and attention score will be assessed at 3 month followup
|
3rd month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2017
Primary Completion (Actual)
July 1, 2019
Study Completion (Actual)
July 1, 2019
Study Registration Dates
First Submitted
May 4, 2018
First Submitted That Met QC Criteria
June 1, 2018
First Posted (Actual)
June 4, 2018
Study Record Updates
Last Update Posted (Actual)
August 2, 2019
Last Update Submitted That Met QC Criteria
July 31, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 005680
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adolescent - Emotional Problem
-
University of CoimbraRecruitingAdolescent Behavior | Adolescent - Emotional ProblemPortugal
-
University of ValenciaMinisterio de Ciencia e Innovación, SpainActive, not recruitingAdolescent - Emotional ProblemSpain
-
Örebro County CouncilCompletedAdolescent - Emotional ProblemSweden
-
University of KlagenfurtCardiff University; Medical University of Vienna; Bielefeld University; Institute... and other collaboratorsRecruitingParent-Child Relations | Parenting | Adolescent Behavior | Adolescent - Emotional Problem | Psychological Well-BeingMoldova, Republic of, North Macedonia
-
Northwell HealthAmerican Psychological FoundationCompletedAdolescent - Emotional ProblemUnited States
-
Valentina HlebecLINNEUNIVERSITETET (LNU), Sweden (leading the consortium); EUROCARERS-ASSOCIATION... and other collaboratorsCompletedMental Health Wellness 1 | Primary Prevention | Cognitive Therapy | Caregivers | Adolescent - Emotional ProblemSlovenia, Italy, Netherlands, Sweden, Switzerland, United Kingdom
-
The University of Hong KongUnknownAdolescent - Emotional ProblemChina
-
Region ÖstergötlandCompletedAnxiety | Depressive Symptoms | Nonsuicidal Self Injury | Adolescent - Emotional Problem | Adolescent Problem Behavior | Self-CriticismSweden
-
Drexel University College of MedicineChildren's Hospital of PhiladelphiaCompletedSmoking | Adolescent - Emotional ProblemUnited States
-
University of North Carolina, Chapel HillUniversity of Colorado, Denver; Doris Duke Charitable Foundation; University... and other collaboratorsNot yet recruitingDepression | Anxiety | Adolescent Behavior | Mental Health Issue | Psychosocial Functioning | Adolescent - Emotional ProblemIndia
Clinical Trials on specific memory and attention realtime training
-
Federal University of Minas GeraisCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Completed
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Completed
-
University of PittsburghNational Cancer Institute (NCI); National Institutes of Health (NIH)Recruiting
-
National Center for Research Resources (NCRR)HRSA/Maternal and Child Health BureauCompleted
-
Tampere University HospitalTampere University; Coxa, Hospital for Joint ReplacementCompletedDelirium | Cognitive Impairment | Malnutrition | Dementia
-
VA Office of Research and DevelopmentUniversity of MarylandCompleted
-
Centre Oscar LambretSCALab UMR CNRS 9193 Université de LilleTerminatedKidney Cancer | Colorectal Cancer | Prostate Cancer | Bladder Cancer | Advanced SarcomaFrance
-
University of Sao PauloUniversity Ghent; Universidade Presbiteriana MackenzieCompleted